Daiichi Sankyo (TSE:4568) Stock Still Looks Cheap Despite A 27% Slide

Daiichi Sankyo Company has seen its share price slide over the past few years, and the question now is whether the current market value lines up with the cash the business is expected to generate. Recent clinical progress for key cancer therapies adds another layer to that debate, since new treatments can reshape long term cash flow expectations.

• Over the past 3 years, Daiichi Sankyo Company shares have fallen 27.4%. This puts the focus squarely on whether the market is now misreading or correctly reading its cash flow profile.
• The recent positive opinion in Europe for Enhertu as an adjuvant treatment in HER2 positive early breast cancer may support expectations for future oncology related cash inflows, if adoption and pricing track the clinical results that supported the recommendation.
• What if you looked at Daiichi Sankyo Company through its earnings instead? See what Daiichi Sankyo Company's 19.0x P/E says about the price.

The issue now is whether the current share price is adequately supported by Daiichi Sankyo Company's expected cash flows when viewed through a Discounted Cash Flow (DCF) lens.

If you are weighing Daiichi Sankyo Company's recent share price weakness against its oncology potential and cash flow outlook, it can help to compare it with other 17 high quality undervalued stocks

Is Daiichi Sankyo Company Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model here projects Daiichi Sankyo Company’s future cash generation and then brings those figures back to today’s terms. Latest twelve month free cash flow is a loss of ¥46.8b, yet the model assumes a recovering profile that moves into sizeable positive free cash flow in the coming years, with projections for the early 2030s already in the hundreds of billions of ¥.

Those long range cash flow estimates sit against a current share price of ¥2,747.00, and the DCF output suggests the implied value of those projected cash streams is substantially above that level. Because Enhertu’s positive CHMP opinion points to an expanded treatment setting in HER2 positive early breast cancer, that potential extra oncology cash generation helps explain why the model indicates more value in Daiichi Sankyo Company’s cash flows than the market price currently reflects. Find out what Daiichi Sankyo Company could be worth using our Discounted Cash Flow (DCF) estimate.

The Daiichi Sankyo Company Narrative: What Would Justify Today's Price?

Daiichi Sankyo Company’s Simply Wall St Narratives pick up where the DCF puzzle leaves off and explain which paths for growth, profitability and earnings would need to hold for the shares to be worth materially more or less than today’s price, all housed on the Community page. Rather than focusing on a single valuation output, each narrative lays out the assumptions behind its fair value so you can later compare them with actual results as they appear in the financials.

One of the top community narratives on Daiichi Sankyo Company: 47% undervalued

"The company's pipeline productivity, evidenced by multiple late-stage ADC candidates targeting previously untapped indications, positions Daiichi Sankyo to capture outsized future revenue…"

Discover why this Narrative puts Daiichi Sankyo Company at 47% undervalued.

Daiichi Sankyo Company’s price is only one piece of the decision

Cash flow projections tell you what the business might earn, but the people steering Daiichi Sankyo Company and how they are rewarded can heavily influence how those cash flows play out over time. See who runs Daiichi Sankyo Company and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com